Moffitt study identifies predictive biomarkers for immunotherapy in merkel cell carcinoma

  • Post author:
  • Post category:uncategorized

Merkel cell carcinoma is a rare but highly aggressive form of skin cancer known for its rapid growth and tendency to metastasize. Despite the promise of immune checkpoint blockade therapy, which can boost the body’s immune response against cancer cells, nearly half of patients do not respond to this treatment.